Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ELI 002

Next Previous
Drug Profile

ELI 002

Alternative Names: AMP KRAS; AMP-CpG; Amph-CpG-7909; Amphiphile mKRAS vaccine; Amphiphile-CpG; ELI-002; ELI-002 2P; ELI-002 7P; VED-002

Latest Information Update: 17 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Elicio Therapeutics
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 11 Dec 2025 Immunogenicity data from the phase I/II AMPLIFY-7P trial in Pancreatic cancer was released by Elicio Therapeutics
  • 29 Sep 2025 Elicio Therapeutics in collaboration with Memorial Sloan Kettering Cancer Center plans a phase I trial for Adenocarcinoma (Combination therapy, Neo-adjuvant therapy) in the first half of 2026
  • 24 Sep 2025 Elicio Therapeutics completes a phase-I/II clinical trials in Adenocarcinoma and Solid tumours (Adjuvant therapy) in USA (NCT04853017)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top